1. Home
  2. Analysis
  3. Kevzara
  4. Emgality

Kevzara and Emgality drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Kevzara (sarilumab) and Emgality (galcanezumab-gnlm). Common drug interactions include arthralgia among females.

The phase IV clinical study analyzes what interactions people have when they take Kevzara and Emgality. It is created by eHealthMe based on reports of 11 people who take the same drugs from the FDA, and is updated regularly.

What is Kevzara?

Kevzara has active ingredients of sarilumab. eHealthMe is studying from 17,561 Kevzara users. Check the latest studies of Kevzara.

What is Emgality?

Emgality has active ingredients of galcanezumab-gnlm. eHealthMe is studying from 24,702 Emgality users. Check the latest studies of Emgality.

On Jul, 17, 2026

11 people who take Kevzara and Emgality together, and have interactions are studied.

Kevzara and Emgality drug interactions.

What are the common drug interactions of Kevzara and Emgality, by gender? *:

female:

  1. Arthralgia (joint pain)
  2. Joint swelling
  3. Abdominal discomfort
  4. Astigmatism (refractive error of the eye in which parallel rays of light from an external source do not converge on a single focal point on the retina)
  5. Bursitis (inflammation of a bursa, typically one in the knee, elbow, or shoulder)
  6. Diarrhoea
  7. Drug hypersensitivity
  8. Drug ineffective
  9. Dyspnoea (difficult or laboured respiration)
  10. Eye disorder

male:

n/a

What are the common drug interactions of Kevzara and Emgality, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

n/a

30-39:

n/a

40-49:

n/a

50-59:

n/a

60+:

  1. Injection site bruising
  2. Injection site pruritus (severe itching at injection site)
  3. Injection site discolouration
  4. Joint swelling
  5. Gait disturbance
  6. Injection site erythema (redness at injection site)

What are the existing conditions these people have? *

  1. Rheumatoid Arthritis (a chronic progressive disease causing inflammation in the joints): 9 people, 81.82%
  2. Polyarthritis (arthritis which involves 5 or more joints simultaneously): 2 people, 18.18%
  3. Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 1 person, 9.09%
  4. Pain: 1 person, 9.09%
  5. Fibromyalgia (a long-term condition which causes pain all over the body): 1 person, 9.09%
  6. Bursitis (inflammation of a bursa, typically one in the knee, elbow, or shoulder): 1 person, 9.09%
  7. Arthritis (form of joint disorder that involves inflammation of one or more joints): 1 person, 9.09%

* Approximation only. Some reports may have incomplete information.

Do you take Kevzara and Emgality?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Kevzara and Emgality:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Kevzara:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Emgality:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Kevzara and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Emgality and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on sarilumab and galcanezumab-gnlm (the active ingredients of Kevzara and Emgality, respectively), and Kevzara and Emgality (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.

Recent studies on eHealthMe:

© 2026 eHealthMe.com. All rights reserved. Use of this site constitutes acceptance of eHealthMe.com's terms of service and privacy policy.